Ultragenyx Pharmaceutical (RARE) Q4 2025 earnings summary

Executive summary

• 2025 total revenue reached $673 million, a 20% increase year-over-year, driven by strong growth in Crysvita and Evkeeza sales, with products now reaching patients in over 35 countries.

• Strategic restructuring, including a 10% workforce reduction (~130 employees), aims to align resources, reduce expenses, and achieve profitability by 2027.

• 2026 is expected to be a pivotal year with two potential approvals (MPS IIIA and GSDIa) and pivotal Phase 3 data in Angelman syndrome, advancing first-ever treatments for rare diseases.

Financial highlights

• 2025 total revenue reached $673 million, up 20% from 2024 and above guidance.

• Product contributions: Crysvita $481M (+17%), Dojolvi $96M (+9%), Evkeeza $59M (+84%), Mepsevii $37M.

• Fourth quarter 2025 revenue was $207 million, up 25% compared to Q4 2024.

• Net loss for 2025 was $575 million, or $5.83 per share.

• Year-end cash, cash equivalents, and marketable securities totaled $738 million.

Outlook and guidance

• 2026 revenue from current products projected at $730–$760 million, representing 8%-13% growth, excluding new launches.

• Crysvita guidance: $500M-$520M; Dojolvi: $100M-$110M.

• Combined R&D and SG&A expenses for 2026 expected to be flat to down low single digits versus 2025.

• 2027 R&D expenses projected to decrease 38% from 2025, with combined R&D and SG&A down at least 15%.

• Path to profitability in 2027 relies on continued double-digit growth from current products, contributions from new launches, and monetization of two PRVs.